A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether patients with haematological malignancy (HM) who need cardiopulmonary bypass (CPB) have a higher short-term mortality or a higher chance of disease progression secondary to CPB. Altogether, 107 papers were found using the reported search terms, but ultimately only eight were relevant to our subject. We found four case series and four case-control series. Most of the found papers were only short series. The largest series included 56 patients with HM and requiring CPB, suggesting that HM patients rarely require CPB surgery and/or are not operated on. Most of these studies showed that the overall postoperative morbidity rate was increased, reaching 50-60% of the patients. These comorbidities were mainly related to postoperative infections, bleeding and blood transfusions, which were highly significant. However, in most papers, the postoperative hospital stay was not different and the in-hospital mortality rate of HM patients was similar to that of healthy patients. One paper demonstrated that the time taken before initiating chemotherapy was longer in patients who underwent CPB surgery. No paper reported an acute change in blood disorders. Long-term mortality rates were not mentioned in some papers, but when it was stated, the HM patients' long-term mortality seemed not increased by using CPB surgery, with more than 80% survival at 3 years and 20-25% progression of the disease at 3 years. Although these study limitations are linked to the low-evidence levels in some of the papers used, haematological malignancies should not be considered a contraindication for cardiac CPB surgery.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol, which was described in detail in ICVTS [1] . 
THREE-PART QUESTION
In
CLINICAL SCENARIO
You are performing an aortic valve replacement in a 60-year old patient. During the preoperative consultation, you learn that the patient suffers from chronic lymphocytic leukaemia (CLL). The preoperative evaluation shows 80 000 lymphocytes per ml. You are reluctant to perform this open-heart procedure. The patient undergoes leukapheresis so as to reduce lymphocyte rates by half, and then has an aortic valve replacement with cardiopulmonary bypass (CPB). There are no postoperative complications, and the patient is still alive. You wonder whether heart surgery might affect the patient's postoperative haematological outcome. 
SEARCH STRATEGY
The
SEARCH OUTCOME
In total, 107 abstracts were identified, of which eight were deemed relevant. Each abstract was read, and only studies with CPB were used. We were able to review four case-control studies and four case series, which we used to address the question. The results are summarized in Table 1 . haematological malignancy (HM) and had undergone cardiac surgery with CPB. The study also featured a control group of 216 patients without cancer who had undergone cardiac surgery with CPB. There was no statistically significant difference in hospital mortality. The rates of infective complications and blood transfusion were significantly increased in the cancer group, but the HM patient subgroup had more infective complications and blood transfusions compared with the solid malignancy subgroup.
Guler et al. [3] evaluated 15 HM patients who underwent cardiac surgery. All were in remission. The 3-year survival rate was 80%. All deaths had a non-HM cause.
Sommer et al. [4] studied 142 patients identified as suitable controls for 56 cardiac surgery patients with HMs, of which three were considered cured, three were in complete remission and 15 received treatments for their haematological disorder at the time of surgery. In-hospital mortality was elevated in HM patients, but not to a statistically significant degree. One death was related to fatal cytopenia. Patients with a history of irradiation exhibited elevated rates of respiratory and renal failure; here again, the difference was not statistically significant.
The Fecher et al. study [5] observed a cohort of 24 HM patients who had undergone cardiac surgery. The authors found no significant difference between patients experiencing complications and those without. The survival rate at 3 years was 83%, with two deaths related to the progression of malignancy.
Potapov et al. [6] compared 28 CLL patients who had undergone cardiac surgery with CPB with a control group of 25 CLL patients who had not received surgery. The study concluded that there were no significant differences between the two groups with regard to long-term infection rates. Chemotherapy indications were similar between the two groups during follow-up. There were also no significant differences regarding the need to initiate chemotherapy (and, thus, no difference in the evolution of CLL). Overall survival was similar in both groups. Ghosh et al. [7] studied a small cohort of 13 HM patients who had undergone cardiac surgery. During the follow-up, three experienced the evolution of malignancy, requiring treatment by chemotherapy. Given that the study sample was very small, no firm conclusions could be drawn.
Samuels et al. [8] investigated 12 CLL patients who had had cardiac surgery with CPB. The authors compared them with a group of non-CLL patients who had had cardiac surgery with CPB during the same period. Two patients died from sepsis during hospitalization, and morbidity during the postoperative stay was linked to infectious complications. Comparison of the two groups was not possible, because the difference in sample sizes was too large. This study was also biased by associated comorbidities, because five patients displayed another neoplasia.
Finck et al. [9] observed 26 CLL patients who had undergone cardiac surgery with CPB. Two patients died during their hospital stay, and two others died later, including one death because of progressive leukaemia. Long-term follow-up of the 23 living patients revealed that five presented with leukaemia progression. Of the 26 patients, six succumbed to postoperative infections. Comparing these six patients with the 20 others, the preoperative absolute neutrophil count (P <0.05) was the only predictive variable.
CLINICAL BOTTOM LINE
Although the evidence is somewhat scarce, we conclude that using CPB surgery does not increase long-term mortality in HM patients. Furthermore, there does not seem to be any risk of malignancy progression to a more aggressive form following cardiac CPB surgery. The routine use of leucocyte depletion filters and cell-saver technique during CPB surgery known to decrease the risk of haematogenous tumour dissemination [10, 11] might explain these results. These studies also show that the overall postoperative morbidity rate was increased, mainly related to postoperative infections and blood transfusions, and already known to increase morbidity and mortality by itself [12] [13] [14] .
Although the limitations of this study are linked to the lowevidence levels of the papers from which it draws, the authors of this best evidence topic think that haematological malignancies should not be considered a contraindication for cardiac CPB surgery. However, preoperatively, the stage of the malignancy should be evaluated to assess postoperative risk properly.
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